期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

罗格列酮治疗2型糖尿病80例的疗效观察 被引量：5

暂未订购
导出
摘要 目的观察罗格列酮治疗2型糖尿病的疗效和安全性。方法选取2型糖尿病患者80例,按治疗前用药情况分为罗格列酮治疗组(R组)与合用磺脲治疗组(B组),每组各40例。R组先行饮食及运动治疗,B组保持原药物剂量不变,然后两组均给予罗格列酮4mg,1次/d,空腹口服,共30周。治疗前后抽取患者静脉血,葡萄糖氧化酶法测空腹血糖(FBG)及餐后2h血糖(P2hBG);测糖化血红蛋白;放免法测空腹胰岛素(FINS);计算胰岛素敏感性指数(A)和胰岛素抵抗指数(R)。结果治疗后两组患者FBG、P2hBG、糖化血红蛋白、FINS水平及R值均较治疗前下降,A升高。上述各指标治疗前后的变化两组间比较差异无统计学意义。两组患者均未发生严重不良反应。结论罗格列酮可单用或与磺脲类合用,治疗2型糖尿病安全有效。
作者 王振华
机构地区 山东省淄博市桓台县人民医院内一科
出处 《实用心脑肺血管病杂志》 2011年第1期63-64,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词 罗格列酮 2型糖尿病 疗效
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献6

  • 1Turner RC, Cult CA, Frighi V, et al. Glycemic control with diet,Sulfonylurea, metformim or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prosective Diabetes Study (UKPDS)Group [J]. JAMA, 1999, 281: 2005 --2012.
  • 2Stenman S, Melander A, Groop PH, et al. What is the benefit of increasing the sulfonylurea dose [J]. Ann Intern Med, 1993, 118:169 2 172.
  • 3李全民,张素华,任伟,倪银星,吴静.罗格列酮对胰岛素抵抗大鼠胰岛素增敏作用及对解偶联蛋白基因表达的影响[J].郑州大学学报（医学版）,2003,38(3):374-377. 被引量：7
  • 4邓安春.抗糖尿病新药罗格列酮和吡格列酮[J].国外医学：药学分册,2000,7(2):55-55.
  • 5文迪雅Ⅳ期临床研究协作组.罗格列酮治疗2型糖尿病的临床观察[J].中华内科杂志,2003,42(9):636-639. 被引量：26
  • 6Plutzky J. Peroxisome proliferator- activated receptors in endothelial cell biology [J]. Curr Opin Lipidol, 2001, 12 (5): 511-518.

二级参考文献14

  • 1Tafuri SR. Troglitazone enhances differentiation, basal glucose uptake, and Glut I protein levels in 3T3-L1 adipocytes. Endocrinology, 1996, 137:4 705.
  • 2Sidell RJ, Cole MA, Draper NJ, et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes, 2002, 51 (4) : 1 110.
  • 3Schrauwen P, Xia J, Bogardus C, et al. Skeletal muscle uncoupling protein 3 expression is a determinant of energy expenditure in Pima Indians. Diabetes, 1999, 48( 1 ) : 146.
  • 4Tsakiridis T, Vranie M, Klip A. Phosphatidylinositol3-kinase and the actin network are not required for the stimulation of glucose transport caused by mitochondrial uncoupling:comparison with insulin action. Biochem J, 1995, 309(Pt 1):1.
  • 5Storlien LH, James DE, Burleigh KM, et al. Fat feeding causes widespread in vivo insulin resistance,decreased energy expenditure and obesity in the rat. Am J Physiol, 1986,251(5 Pt 1):E576.
  • 6Cabrero A, Liaverias G, Roglans N, et al. Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats. Bichem Biophys Ras Commun, 1999, 260(2) :547.
  • 7Schrauwen P, Wagenmakers A J, van-Marken-Lichtenbelt WD, et al. Increase in fat oxidation on a high-fat diet is accompanied by an increase in triglyceride-derived fatty acid oxidation. Diabetes, 2000, 49 (4) : 640.
  • 8Ye JM, Doyle PL, Iglesias MA, et al. Peroxisome proliferator-activated receptor( PPAR)-alpha activiation lowers muscle lipids and improves insulin sensitivity in high fat-fat rat:comparision with PPAR-gamma activition. Diabetes, 2001,50(2) : 411.
  • 9Cabrero A, Alegret R, Sanchez RM, et al. Bezafibrate reduces mRNA levels of Adipocyte Markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes,2001, 50(8):1 883.
  • 10Chaput E, Saladin R, Silvestre M, et al. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun, 2000,271(2) : 445.

共引文献40

同被引文献28

  • 1Hajilooi M, Sanati A, Ahmadieh A, et al. Circulating ICAM -1, VCAM - 1, E - selectin, P - selectin, and TNFRII in patients with coronary artery disease [J]. Immunol Invest, 2004, 33 (3) : 263 - 275.
  • 2Komorovsky R, Desideri A. Carotid ultrasound assessment of patients with coronary artery disease: a useful index for risk stratification [ J ]. Vase Health Risk Manag, 2005, 1 (2): 131-136.
  • 3Pignoli P, Tremoli E, Oreste P, et al. Intimalplusmedial thickness of the arterial wall: a direct measurement with ultrasound imaging [ J ]. Circulation, 1986, 74 (6): 1399-1406.
  • 4Rubio - Guerra AF, Vargas - Robles H, Lozano Nuevo JJ. Correlation between circulating adhesion molecule levels and albuminuria in type -2 diabetic hypertensive patients [J]. Kidney Blood Press Res, 2009, 32 (2): 106-109.
  • 5Otsuki M, Heshimoto K, Morimoto Y, et al. Circulating vascular cell adhesion molecule - 1 in atherosclerotic NIDDMpaficnts [ J ]. Diabetes, 1997, 46 (12): 2096-2101.
  • 6Becker A, Jager A, Kostense PJ, et al. Why is soluble intercellular adhesion molecule - 1 related to cardiovascular mortality [ J]. Eur J CBn Invest, 2002, 32 ( 1 ) : 1 - 8.
  • 7Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti - inflammatory effects mediated by inhibition of NF - kappeB activation [ J ]. Am J Physiol Renal Physiol, 2007, 292 (4) : 1141 -1150.
  • 8李蕾,马杉,薛元明.罗格列酮治疗2型糖尿病的疗效观察[J].中国误诊学杂志,2008,8(4):825-826. 被引量：2
  • 9苏凤.??罗格列酮合用美吡达治疗2型糖尿病30例观察(J)中国医药指南. 2009(12)
  • 10刘金阁,雷建华.罗格列酮治疗2型糖尿病临床分析[J].河北医药,2008,30(7):987-988. 被引量：3

引证文献5

二级引证文献4

实用心脑肺血管病杂志
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部